# Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

> **NCT07575399** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Amgen** · enrollment: 300 (estimated)

## Conditions studied

- Obesity or Overweight

## Interventions

- **DRUG:** Maridebart Cafraglutide

## Key facts

- **NCT ID:** NCT07575399
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-25
- **Primary completion:** 2028-01-03
- **Final completion:** 2028-02-28
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07575399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07575399, "Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)". Retrieved via AI Analytics 2026-08-25 from https://api.ai-analytics.org/clinical/NCT07575399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*